Form 4 for GALT GALECTIN THERAPEUTICS INC
Accepted 2022-02-08 00:00:00 ET · period of report 2022-01-24 · accession 0001133416-22-000043 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-08 | 2022-01-24 | GALT | Uihlein Richard E | Dir, 10% | A - Grant | $1.98 | +17.7K | 7.94M | +0.2% | +$35.0K |
| D | 2022-02-08 | 2022-01-24 | GALT | Uihlein Richard E | Dir, 10% | A - Grant | $0.00 | +40.0K | 40.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-24 | A | A | 17,677 | $1.98 | 7,936,677 | D | — | — | (F1) These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $35,000 for 2022. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2022. |
| 2 | Derivative | Stock Option (right to buy) | 2022-01-24 | A | A | 40,000 | $0.00 | 40,000 | D | $1.98 · — to 2032-01-24 | 40,000 Common Stock | (F3) The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. (F4) The options vest 100% on December 31, 2022. |